The notice issued by Gufic Biosciences Limited details the outcome of the Board of Directors meeting held on July 31, 2026. The primary matter considered and approved by the board is the re-appointment of Mr. Pankaj Jayakumar Gandhi as the Whole Time Director of the company for a further term of five years. His new term is set to commence from September 07, 2026, and run through September 06, 2031, subject to the approval of shareholders at the ensuing 42nd Annual General Meeting.

The re-appointment falls under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that Mr. Pankaj Jayakumar Gandhi is not debarred from holding the office of a director by virtue of any orders passed by SEBI or any other regulatory authority. Detailed disclosures regarding the re-appointment indicate that he is not related to any other directors on the board.

Incorporated in 2000, Gufic Biosciences Limited is closely held by the Choksi family, who maintain a significant promoter stake. The company operates extensively within the pharmaceutical, herbal, and biotechnology sectors, with a core emphasis on contract manufacturing and the production of sterile injectables and formulations. Throughout 2025, Gufic focused on strengthening its domestic and export market presence while optimizing its product mix across various therapeutic segments.

During 2025, the company navigated a mixed operating environment with strategic cost-control measures that helped protect bottom-line performance despite occasional top-line fluctuations. Institutional and promoter backing remained stable, with the Choksi family holding around 70% of the company.